Which has preferable valuation and earnings, NBTX or MIRM?

Mirum Pharmaceuticals has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $29.64M 68.43 -$27.11M N/A N/A Mirum Pharmaceuticals $569.61M 13.07 -$23.36M -$13.61 N/A

Does the media refer more to NBTX or MIRM?

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Nanobiotix. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 4 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.91 beat Mirum Pharmaceuticals' score of 0.68 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, NBTX or LNTH?

Lantheus has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $29.64M 68.43 -$27.11M N/A N/A Lantheus $1.54B 4.46 $233.56M $4.15 25.46

Is NBTX or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Nanobiotix's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Nanobiotix's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Lantheus 18.05% 29.32% 15.00%

Does the media refer more to NBTX or LNTH?

In the previous week, Nanobiotix and Nanobiotix both had 4 articles in the media. Lantheus' average media sentiment score of 1.19 beat Nanobiotix's score of 0.91 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, PTCT or NBTX?

PTC Therapeutics has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PTC Therapeutics $1.73B 4.07 $682.64M -$2.33 N/A Nanobiotix $29.64M 68.43 -$27.11M N/A N/A

Does the media prefer PTCT or NBTX?

In the previous week, PTC Therapeutics had 8 more articles in the media than Nanobiotix. MarketBeat recorded 12 mentions for PTC Therapeutics and 4 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.91 beat PTC Therapeutics' score of 0.57 indicating that Nanobiotix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, COGT or NBTX?

Nanobiotix has higher revenue and earnings than Cogent Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Nanobiotix $29.64M 68.43 -$27.11M N/A N/A

Is COGT or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Nanobiotix N/A N/A N/A

Does the media prefer COGT or NBTX?

In the previous week, Nanobiotix had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Nanobiotix and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.60 beat Nanobiotix's score of 0.91 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nanobiotix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, NBTX or SRRK?

Nanobiotix has higher revenue and earnings than Scholar Rock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $29.64M 68.43 -$27.11M N/A N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is NBTX or SRRK more profitable?

Nanobiotix's return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Scholar Rock N/A -163.52% -96.67%

Does the media favor NBTX or SRRK?

In the previous week, Scholar Rock had 9 more articles in the media than Nanobiotix. MarketBeat recorded 13 mentions for Scholar Rock and 4 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.91 beat Scholar Rock's score of -0.10 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 2 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nanobiotix (NBTX) Competitors

$40.07 0.00 (0.00%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$40.07 0.00 (0.00%)

As of 07/10/2026 06:55 PM Eastern

Compare

NBTX vs. MIRM, LNTH, PTCT, COGT, and SRRK

Should you buy Nanobiotix stock or one of its competitors? MarketBeat compares Nanobiotix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nanobiotix include Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), PTC Therapeutics (PTCT), Cogent Biosciences (COGT), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does Nanobiotix compare to Mirum Pharmaceuticals?

Nanobiotix (NASDAQ:NBTX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Nanobiotix. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 4 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.91 beat Mirum Pharmaceuticals' score of 0.68 indicating that Nanobiotix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nanobiotix has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Nanobiotix's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Mirum Pharmaceuticals has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$29.64M	68.43	-$27.11M	N/A	N/A
Mirum Pharmaceuticals	$569.61M	13.07	-$23.36M	-$13.61	N/A

Nanobiotix has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

Nanobiotix currently has a consensus target price of $37.33, suggesting a potential downside of 6.83%. Mirum Pharmaceuticals has a consensus target price of $143.40, suggesting a potential upside of 17.42%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Mirum Pharmaceuticals beats Nanobiotix on 8 of the 15 factors compared between the two stocks.

How does Nanobiotix compare to Lantheus?

Nanobiotix (NASDAQ:NBTX) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, Nanobiotix and Nanobiotix both had 4 articles in the media. Lantheus' average media sentiment score of 1.19 beat Nanobiotix's score of 0.91 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 18.05% compared to Nanobiotix's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Lantheus	18.05%	29.32%	15.00%

Nanobiotix presently has a consensus price target of $37.33, suggesting a potential downside of 6.83%. Lantheus has a consensus price target of $108.29, suggesting a potential upside of 2.50%. Given Lantheus' stronger consensus rating and higher probable upside, analysts clearly believe Lantheus is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Nanobiotix has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lantheus has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$29.64M	68.43	-$27.11M	N/A	N/A
Lantheus	$1.54B	4.46	$233.56M	$4.15	25.46

Summary

Lantheus beats Nanobiotix on 10 of the 13 factors compared between the two stocks.

How does Nanobiotix compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Nanobiotix (NASDAQ:NBTX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Nanobiotix has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Nanobiotix's return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Nanobiotix	N/A	N/A	N/A

PTC Therapeutics has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	4.07	$682.64M	-$2.33	N/A
Nanobiotix	$29.64M	68.43	-$27.11M	N/A	N/A

PTC Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

PTC Therapeutics presently has a consensus target price of $91.57, indicating a potential upside of 7.92%. Nanobiotix has a consensus target price of $37.33, indicating a potential downside of 6.83%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe PTC Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, PTC Therapeutics had 8 more articles in the media than Nanobiotix. MarketBeat recorded 12 mentions for PTC Therapeutics and 4 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.91 beat PTC Therapeutics' score of 0.57 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

38.8% of Nanobiotix shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

PTC Therapeutics beats Nanobiotix on 8 of the 15 factors compared between the two stocks.

How does Nanobiotix compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Nanobiotix (NASDAQ:NBTX) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

In the previous week, Nanobiotix had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Nanobiotix and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.60 beat Nanobiotix's score of 0.91 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nanobiotix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

38.8% of Nanobiotix shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nanobiotix's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Nanobiotix	N/A	N/A	N/A

Cogent Biosciences currently has a consensus price target of $43.73, indicating a potential upside of 12.50%. Nanobiotix has a consensus price target of $37.33, indicating a potential downside of 6.83%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cogent Biosciences is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has higher revenue and earnings than Cogent Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Nanobiotix	$29.64M	68.43	-$27.11M	N/A	N/A

Summary

Nanobiotix beats Cogent Biosciences on 7 of the 13 factors compared between the two stocks.

How does Nanobiotix compare to Scholar Rock?

Nanobiotix (NASDAQ:NBTX) and Scholar Rock (NASDAQ:SRRK) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

In the previous week, Scholar Rock had 9 more articles in the media than Nanobiotix. MarketBeat recorded 13 mentions for Scholar Rock and 4 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.91 beat Scholar Rock's score of -0.10 indicating that Nanobiotix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	2 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nanobiotix presently has a consensus target price of $37.33, suggesting a potential downside of 6.83%. Scholar Rock has a consensus target price of $56.00, suggesting a potential downside of 1.25%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Nanobiotix's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Scholar Rock	N/A	-163.52%	-96.67%

Nanobiotix has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Nanobiotix has higher revenue and earnings than Scholar Rock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$29.64M	68.43	-$27.11M	N/A	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Summary

Scholar Rock beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBTX vs. The Competition

Export

Metric	Nanobiotix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.03B	$3.05B	$6.89B	$12.64B
Dividend Yield	N/A	2.06%	2.68%	8.01%
P/E Ratio	N/A	20.02	27.36	24.52
Price / Sales	68.43	359.26	500.86	85.07
Price / Cash	N/A	56.80	29.24	49.38
Price / Book	-20.34	4.29	10.98	6.43
Net Income	-$27.11M	$64.59M	$3.59B	$331.05M
7 Day Performance	-2.51%	-1.07%	-0.92%	-1.34%
1 Month Performance	12.75%	4.51%	4.59%	0.52%
1 Year Performance	660.34%	24.67%	29.84%	22.23%

Nanobiotix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBTX Nanobiotix	1.9981 of 5 stars	$40.07 flat	$37.33 -6.8%	+660.3%	$2.03B	$29.64M	N/A	100	Gap Up
MIRM Mirum Pharmaceuticals	2.5209 of 5 stars	$119.40 -2.9%	$139.80 +17.1%	+131.9%	$7.29B	$569.61M	N/A	140
LNTH Lantheus	3.0855 of 5 stars	$111.37 +1.6%	$101.86 -8.5%	+29.9%	$7.25B	$1.54B	26.84	1,193
PTCT PTC Therapeutics	2.6548 of 5 stars	$82.47 +1.1%	$91.36 +10.8%	+74.8%	$6.84B	$1.73B	N/A	1,410	Gap Down
COGT Cogent Biosciences	1.8602 of 5 stars	$39.28 +1.4%	$43.73 +11.3%	+254.0%	$6.72B	N/A	N/A	80	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBTX) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanobiotix (NBTX) Competitors

NBTX vs. MIRM, LNTH, PTCT, COGT, and SRRK

How does Nanobiotix compare to Mirum Pharmaceuticals?

Summary

How does Nanobiotix compare to Lantheus?

Summary

How does Nanobiotix compare to PTC Therapeutics?

Summary

How does Nanobiotix compare to Cogent Biosciences?

Summary

How does Nanobiotix compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanobiotix (NBTX) Competitors

NBTX vs. MIRM, LNTH, PTCT, COGT, and SRRK

How does Nanobiotix compare to Mirum Pharmaceuticals?

Does the media refer more to NBTX or MIRM?

Is NBTX or MIRM more profitable?

Which has preferable valuation and earnings, NBTX or MIRM?

Which has more volatility & risk, NBTX or MIRM?

Do analysts rate NBTX or MIRM?

Do insiders & institutionals have more ownership in NBTX or MIRM?

Summary

How does Nanobiotix compare to Lantheus?

Does the media refer more to NBTX or LNTH?

Is NBTX or LNTH more profitable?

Do analysts rate NBTX or LNTH?

Which has more volatility and risk, NBTX or LNTH?

Do insiders and institutionals have more ownership in NBTX or LNTH?

Which has stronger earnings & valuation, NBTX or LNTH?

Summary

How does Nanobiotix compare to PTC Therapeutics?

Is PTCT or NBTX more profitable?

Which has preferable valuation and earnings, PTCT or NBTX?

Which has more risk & volatility, PTCT or NBTX?

Do analysts prefer PTCT or NBTX?

Does the media prefer PTCT or NBTX?

Do insiders and institutionals believe in PTCT or NBTX?

Summary

How does Nanobiotix compare to Cogent Biosciences?

Which has more risk & volatility, COGT or NBTX?

Does the media prefer COGT or NBTX?

Do institutionals & insiders believe in COGT or NBTX?

Is COGT or NBTX more profitable?

Do analysts recommend COGT or NBTX?

Which has stronger earnings and valuation, COGT or NBTX?

Summary

How does Nanobiotix compare to Scholar Rock?

Does the media favor NBTX or SRRK?

Do insiders and institutionals hold more shares of NBTX or SRRK?

Do analysts rate NBTX or SRRK?

Is NBTX or SRRK more profitable?

Which has more risk & volatility, NBTX or SRRK?

Which has higher earnings & valuation, NBTX or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools